HomeBusinessGoldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt June 2, 2026byadmin Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt Source link
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock Source link
BancFirst director David Rainbolt sells $978k in stock BancFirst director David Rainbolt sells $978k in stock Source link
South Africa’s manufacturing output falls 1.7% in June South Africa’s manufacturing output falls 1.7% in June Source link
